1	Understanding Pain in Polycystic Ovary Syndrome: Health Risks and Treatment Effectiveness
2	Tess Cherlin, PhD ¹ , Stephanie Mohammed, PhD ¹ , Sasha Ottey, MHA ² , Katherine Sherif, MD ³ , Shefali S. Verma
3	PhD ¹
4	¹ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Philadelphia, PA, United
5	States.
6	² PCOS Challenge: The National Polycystic Ovary Syndrome, Atlanta, GA, USA.
7	³ Department of Medicine, Sidney Kimmel Medicine College, Thomas Jefferson University, Philadelphia, PA, USA
8	
9	
10	
11	
12	Corresponding Author:
12 13	Corresponding Author: Shefali S. Verma
13	Shefali S. Verma
13 14	Shefali S. Verma
13 14 15	Shefali S. Verma
13 14 15 16	Shefali S. Verma
13 14 15 16 17	Shefali S. Verma
13 14 15 16 17 18	Shefali S. Verma
13 14 15 16 17 18 19	Shefali S. Verma

23

24 Abstract

25 Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in women, often accompanied by various 26 symptoms including significant pain, such as dysmenorrhea, abdominal, and pelvic pain, which remains underexplored. This retrospective study examines electronic health records (EHR) data to assess the prevalence of 27 28 pain in women with PCOS. Conducted on May 29, 2024, using data from 120 Health Care Organizations within the 29 TriNetX Global Network, the study involved 76,859,666 women from diverse racial backgrounds. The analysis 30 focused on the prevalence of pain among women with PCOS, both overall and in those prescribed PCOS-related 31 medications. Relative risk ratios (RR) were calculated for future health outcomes and stratified by self-reported race. 32 The study found that 19.21% of women with PCOS experienced pain, with the highest prevalence among Black or 33 African American (32.11%) and White (30.75%) populations. Both the PCOS and PCOS and Pain cohorts exhibited 34 increased RR for various health conditions, with significant differences noted across racial groups for infertility, 35 ovarian cysts, obesity, and respiratory diseases. Additionally, women with PCOS who were treated with PCOS-36 related medications showed a decrease in pain diagnoses following treatment. In conclusion, this study highlights 37 the critical need to address pain in the diagnosis and management of PCOS due to its significant impact on patient 38 health outcomes.

Key words: PCOS, polycystic ovary syndrome, pain, abdominal pain, pelvic pain, dysmenorrhea, health disparities,
future health outcomes

41 Impact Statement

Insufficient data exist on the prevalence of pain in women with a PCOS diagnosis, and its associations with future health outcomes. Among, 444,348 women with PCOS in the TriNextX Global Network, 19.21% have dysmenorrhea, abdominal, and pelvic pain. Women with PCOS and Pain are at increased risk for developing ovarian cysts, infertility, T2D, and fatty liver disease and are at further risk when stratified by self-reported race groups.

46

47

48

49 Introduction

50 According to the World Health Organization (WHO), polycystic ovary syndrome (PCOS) affects approximately 8-51 13% of women of reproductive age, with an alarming 70% of affected individuals remaining undiagnosed globally(Organization, 28 June 2023). The assessment of PCOS has been substantiated by multiple guidelines 52 53 (Azziz et al., 2016; Teede et al., 2010) and has undergone refinement since its initial description by Stein and 54 Leventhal in 1935(Stein & Leventhal, 1935). Standard diagnostic criteria have evolved through international efforts, 55 including conferences convened by the National Institutes of Health (NIH) in 1990(Zawadri, 1992), the 56 ESHRE/ASRM-sponsored PCOS consensus workshop group in Rotterdam in 2003 and 2004(ESHRE & Group, 57 2004), and the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary 58 Syndrome in 2018, most recently updated in 2023(Mousa & Tay, 2023; Teede et al., 2018).

59 Recommendations for assessing PCOS encompass a multifaceted approach, including the evaluation of irregular 60 menstrual cycles, ovulatory dysfunction, biochemical and clinical hyperandrogenism, ultrasound findings, serum 61 Anti-Mullerian Hormone (AMH) levels, and various other factors such as ethnic disparities, cardiovascular disease 62 risk, menopausal status, impaired glucose tolerance, and risk of type 2 diabetes mellitus (T2DM)(Mousa & Tay, 63 2023; Teede et al., 2018). Additionally, screening and managing psychological manifestations, implementing 64 lifestyle interventions, and adhering to pharmacological treatment principles are integral aspects of PCOS 65 management(Mousa & Tay, 2023; Teede et al., 2018). While the diagnostic criteria for PCOS primarily focus on 66 reproductive and metabolic manifestations, the substantial burden of *pain* experienced among women with PCOS is 67 a critical factor that warrants effective prevention and management of the disease.

The assessment of pain in PCOS necessitates a multidimensional approach, incorporating self-reported scales, clinical evaluation, and possibly imaging techniques to elucidate the underlying etiology and severity. Several commonly utilized assessment tools incorporate evaluations of pain among women with PCOS. The Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ), developed by Cronin et al. in 1998, assesses various domains, including painful menstrual cycles(Cronin et al., 1998). Additionally, the SF-36 scale, examines eight dimensions of health, including bodily pain(McHorney et al., 1993). Women with PCOS across diverse demographic backgrounds have consistently reported lower SF-36 scores specifically in the domain of

75 bodily pain(Drosdzol et al., 2007; Elsenbruch et al., 2003; Hahn et al., 2005; Li et al., 2011). Furthermore, the 76 Menorrhagia Outcomes Questionnaire, developed by Lamping et al. in 1998, evaluates both heavy menstrual 77 bleeding (HMB) and the associated pain(Lamping et al., 1998). Despite the validation of these instruments, they 78 may not comprehensively capture key symptoms expressed by patients with PCOS, especially those related to 79 dysmenorrhea, abdominal, or pelvic pain. Insufficient data exist to highlight the prevalence of pain reported by 80 women both before and after a PCOS diagnosis, as well as any associations between this pain and the condition 81 itself and its long-term effects. To address this gap in research, we propose an investigation utilizing health records 82 to shed light on this underexplored aspect of PCOS.

83 Electronic health records (EHRs) have become indispensable for managing vast amounts of clinical data, including 84 patient demographics, medical history, medications, allergies, laboratory test results, vital signs, and imaging 85 reports, as well as genetic information obtained from patient genomes when available. Given that EHRs contain 86 comprehensive information about patient care, including the progression of signs and symptoms, severity, 87 comorbidities, and treatments, they provide invaluable resources for conducting large-scale retrospective studies. 88 EHR-based studies have been particularly valuable in assessing the prevalence of conditions that are often 89 underdiagnosed or misdiagnosed in women(Kruse et al., 2018; Maletzky et al., 2022; Penrod et al., 2023). The 90 temporal aspect of clinical events, such as the onset of symptoms, treatment administration, and follow-up visits, can 91 also be mined from EHRs, providing crucial insights into disease trajectories and treatment efficacy(Zhao et al., 92 2017).

93 Pain, particularly in the context of PCOS, remains an underexplored area of research. By leveraging EHR data we 94 can identify women with PCOS who have reported dysmenorrhea, abdominal, and pelvic pain. The objective of this 95 research is to use EHR and look at longitudinal data retrospectively to determine the pain reported by women with 96 PCOS and to determine associations with other factors. This study aims to explore the prevalence of pain in women 97 with and without PCOS, examine the relative risk of long-term health outcomes in those with and without pain, and 98 assess the impact of medications on pain symptoms. By analyzing longitudinal EHR data, we seek to uncover 99 patterns associated with comorbidities, infertility, and medication usage, and explore their potential effects on pain 100 thresholds. Our approach will provide insights into the relationship between pain symptoms and PCOS contributing 101 to a better understanding of the condition and potentially improving patient care.

```
102
```

- 103
- 104 Methods

105 Study Design

The data used in this study was collected on May 29th, 2024 at 3:00pm EST from the TriNetX²⁰ Global Network,
 which provided access to electronic medical records (diagnoses, procedures, medications, laboratory values,

108 genomic information) from approximately 140,962,260 million patients from 120 healthcare organizations.

109 Cohort Definitions

A retrospective cohort analysis was conducted for patients with PCOS and patients with PCOS and Pain. Patients
 who were identified as cases (met inclusion and exclusion criteria) were compared to their respective controls.
 Description of inclusion and exclusion criteria for each cohort can be found in Supplemental Table 1 – Figure
 supplement 1.

114 For the PCOS cohort, PCOS was defined as either having a PCOS diagnosis (ICD 10 E28.2), or an irregular 115 menstruation (ICD 10 N92.6) and hirsutism (ICD 10 L68.0) diagnosis, or an irregular menstruation (ICD 10 N92.6) 116 and androgen excess (ICD 10 E28.1) diagnosis. PCOS controls were defined as having a physical examination (ICD 117 10 Z00.0) and none of the PCOS case criteria. PCOS participants also had to satisfy stringent exclusion criteria to 118 avoid confounders. Exclusion criteria for PCOS consisted of Maternal care for benign tumor of corpus uteri (ICD 10 119 O34.1), Leiomyoma of uterus (ICD 10 D25), Endometriosis (ICD 10 N80), Polyp of corpus uteri (ICD 10 N84.0), 120 and Female pelvic inflammatory disease unspecified (ICD 10 N73.9). Description of inclusion and exclusion criteria 121 for each cohort can be found in Table 1 - Figure supplement 1.

For the PCOS and Pain cohort, PCOS was defined the same as above. PCOS and Pain cases were defined as patients with a PCOS case as well as being diagnosed for either abdominal and pelvic pain (ICD 10 R10) or dysmenorrhea (ICD 10 N94.6) +/- three months from their first PCOS diagnosis. PCOS and Pain controls were defined as patients with PCOS but no pain diagnoses. Description of inclusion and exclusion criteria for each cohort can be found in **Table 1- Figure supplement 1**.

127 To compare cohorts (cases / controls), the first documented encounter or PCOS (case / controls) or PCOS and Pain 128 (case / controls) was defined as an "index event" in TriNetX. Index events are the specific dates a patient satisfies all 129 selected cohort criteria. Baseline characteristics are all assessed *before* the index event while all health outcomes are 130 assessed *after* the index event. Figure 1- Figure supplement 2 shows a graphical representation of this relationship 131 among index events and outcomes specified in this study.

132 Propensity Score Matching

The TriNetX platform uses a cohort matching method called 1:1 propensity score matching(Austin, 2011). For each cohort analysis, cases were matched on the following criteria: age at the index event, self-reported race, overweight, obesity, and other hyperalimentation (ICD 10 E65-E69) status, type 2 diabetes mellitus (T2D) (ICD 10 E11) status, essential (primary) hypertension (ICD 10 I10) status, and hyperlipidemia, unspecified (ICD 10 E78.5) status. Baseline conditions were assessed up to one day before the index event. **Figure 1** shows the number of patients in each case and control cohort both at baseline and after propensity score matching.

139 Future Health Outcomes

140 For each of the five cohorts listed above, we calculated relative risk ratios (RR) with 95% confidence intervals for 141 10 future health outcomes: mental, behavioral and neurodevelopmental disorders (ICD 10 F01-F99), female 142 infertility (ICD 10 N97), noninflammatory disorders of ovary, fallopian tube and broad ligament (ICD 10 N83), 143 Obesity (ICD 10 E65-E68), Type 2 Diabetes (ICD 10 E11), diseases of the circulatory system (ICD 10 I00-I99), 144 diseases of the respiratory system (J00-J99), abdominal and pelvic pain (ICD 10 R10) or dysmenorrhea, unspecified 145 (ICD 10 N94.6), nonalcoholic steatohepatitis (ICD 10 K75.81) or fatty liver, not elsewhere classified (ICD 10 146 K76.0), and chronic kidney disease (ICD 10 N18). The RR for future health outcomes was calculated on participants 147 who satisfied the 1:1 propensity score matching criteria (above). Differences in relative risks were calculated for 148 significance by calculating the difference of two estimates (Altman & Bland, 2003). Future health outcomes were 149 only considered if their first occurrence was at least 3-months after the index event. Figure 1 shows the health 150 outcomes assessed after 1:1 propensity score matching(Austin, 2011; Guo & Fraser, 2014; Haukoos & Lewis, 2015). 151 These analyses were done within the TriNetX platform, and no individual-level data was extracted from the 152 platform.

153 Self-reported Race Stratified Sub-Analysis

154 We did a follow-up analysis looking at health outcomes for patients with PCOS and PCOS and Pain compared to 155 matched controls stratified by self-reported race and ethnicity. The following race categories are present in the 156 TriNetX platform: American Indian or Alaskan Native, Asian, Black or African American, Native Hawaiian or 157 Other Pacific Islander, Other, White, and Unknown Race. For our analysis, we included the following four race 158 categories: Asian, Black or African American, and Other (American Indian or Alaskan Native or Native Hawaiian 159 or Other Pacific Islander, or Other), and White (Figure 2 - Figure supplement 3). Due to the small population sizes 160 of American Indian or Alaskan Native or Native Hawaiian or Other Pacific Islander, or Other, we decided to 161 combine these four self-reported race groups together into one "Other" population. For the PCOS cohorts we looked 162 at the pain health outcome stratified by self-reported race (Figure 2A - Figure supplement 3). For the PCOS and 163 Pain cohorts, we looked at ovarian cysts, infertility, obesity, T2D, mental health conditions, circulatory diseases, 164 respiratory diseases, liver disease, and kidney disease stratified by self-reported race (Figure 2B - Figure 165 supplement 3).

166 PCOS Medication Sub-analysis

167 We performed a follow-up analysis looking at the number of patients with PCOS who were documented as having 168 pain before being prescribed three common PCOS medications (systemic contraceptives (VA: HS200), metformin 169 (RxNorm 6809), or spironolactone (RxNorm 9997) as shown in Figure 3 - Figure supplement 4. Three cohorts 170 were created for patients were included if they had a PCOS diagnosis (described above) and 1) ever had a systemic 171 contraceptives prescription but not a metformin or spironolactone prescription, 2) ever had a metformin prescription 172 but not a systemic contraceptives or spironolactone prescription, and 3) ever had a spironolactone but not a systemic 173 contraceptives or metformin prescription. For patients with PCOS, we counted the number of participants who had a 174 diagnosis code for either dysmenorrhea or abdominal and pelvic pain before the index event. The index event was 175 defined as a participant having a PCOS diagnosis and a medication prescription at the same time. We then counted 176 the number of patients with PCOS who reported either dysmenorrhea or abdominal and pelvic pain after the index 177 event. We further compared the change in prevalence before and after the indexed event.

178 Results

179 Demographics of women with PCOS in the TriNetX Global Network

180 We first identified participants with PCOS and associated comorbidities. The demographics and characteristics of 181 both the PCOS and non-PCOS cohorts are detailed in Table 2 - Figure supplement 5. We queried the 76,859,666 182 women of any age from 120 Health Care Organizations (HCOs) in the TriNetX Global Network for PCOS and 183 associated comorbidities. After applying stringent inclusion/exclusion criteria for PCOS and subsequent controls 184 (see Methods), we were left with a total population of 7,005,733. We found a 7% (n = 468,805 prevalence of PCOS 185 at an average age of 28.7 (SD \pm 9.49) in this population. Of those participants with PCOS, 4.61%, 11.35%, 22.73%, 186 and 61.32% self-identified as Asian, Black or African American, Other, or White respectively (Table 2 - Figure 187 supplement 5).

We then examined the prevalence of PCOS-associated comorbidities represented in the PCOS cohort. We observed that 16.11% of patient with PCOS had a diagnosis code for obesity, 6.23% had a diagnosis code for essential hypertension, 4.01% had a diagnosis code for T2D, and 3.24% had a diagnosis code for hyperlipidemia (**Table 2 -Figure supplement 5**).

We also investigated the prevalence of other women's health conditions related to PCOS such as infertility and
ovarian cysts. Table 2 - Figure supplement 5 shows that women with PCOS had a 2.53% prevalence of infertility,
a 3.55% prevalence of ovarian cysts.

195 The TriNetX platform also allow to easily survey the diagnoses that are most prevalent among a cohort population.
196 As can be observed in **Table 2 - Figure supplement 5**, that respiratory system diseases, mental health conditions,
197 and digestive system diseases were most prevalent among the PCOS cohort (24.24%, 20.97%, and 19.40%
198 respectively).

Since many women with PCOS are prescribed medications to help manage symptoms associated with the disease, we aimed to gain a deeper understanding of the prevalence of PCOS-prescribed medications in the PCOS cohort. We found that 12.76% of the PCOS cohort were prescribed systemic oral contraceptives, 7.07% were prescribed metformin, and 2.77% were prescribed spironolactone (**Table 2 - Figure supplement 5**).

A focus of our paper is understanding the impact pain has on women with PCOS, therefore, we looked at the prevalence of both dysmenorrhea and abdominal and pelvic pain. We observed that overall, there was a 19.21%

prevalence of pain (2.46% prevalence of dysmenorrhea, 16.75% prevalence of abdominal or pelvic pain) (Table 2 -

Figure supplement 5).

207 Demographics of women with PCOS and Pain in the TriNetX Global Network

208 As noted above, 19.21% of women with PCOS also had a pain diagnosis, encompassing either dysmenorrhea or 209 pelvic and abdominal pain. We first examined the demographics of the study participants using data from the 210 TriNetX Global Network. Table 3 - Figure supplement 6 shows the comprehensive demographic results, 211 highlighting the distribution of pain diagnoses for age, race, and other relevant demographic factors. This table 212 provides a clear view of the demographic characteristics and their potential influence on the prevalence of pain 213 among individuals with PCOS. Similar to the PCOS cohort, participants with PCOS and Pain had an average age of 214 29.02 (SD ± 9.23) and among those 3.57% women were Asian, 12.54% Black or African America, 19.24% 215 categorized as Other, and 64.65% self-reported as White (Table 3 - Figure supplement 6). However, when we 216 looked at the prevalence of PCOS and Pain compared to controls (PCOS without pain) within a self-reported race 217 group, we observed that the highest prevalence of PCOS and Pain was 32.11% in the Black or African American 218 population followed by 30.75% in the White population, 24.75% in the Other population, and 22.74% in the Asian 219 population (Table 4 -- Figure supplement 7). With respect to PCOS comorbidities, the cohort of individuals with 220 both PCOS and Pain exhibited a higher prevalence of comorbid conditions compared to the entire population of 221 individuals with PCOS. Specifically, 34.68% of PCOS and Pain participants had an obesity diagnosis, 13.36% had 222 an essential hypertension diagnosis, 9.05% had a T2D diagnosis, and 8.09% had a hyperlipidemia diagnosis. These 223 high prevalences represent a respective increase of 18.57%, 7.13%, 5.04%, and 4.85% compared to all participants 224 with PCOS. Notably, as illustrated in Figure 2, there is at least a two-fold increase in the prevalence of each 225 comorbid condition among those with both PCOS and Pain. This substantial increase highlights the heightened risk 226 and burden of comorbidities within the PCOS and Pain cohort.

We observed a similar trend with respect to the most highly co-occurring diseases with PCOS. Diseases of the respiratory system, digestive system, and mental health conditions had prevalences of 44.81%, 42.85%, and 42.68%, respectively, which is at least a 2-fold increase for all three conditions compared to the entire PCOS cohort (**Figure** 2). We also see a 2-fold increase in the prevalence of infertility (7.08%) and ovarian cysts (10.22%) in the PCOS and Pain cohort when we compared to the PCOS cohort as shown in **Figure 2**. Further, there is at least a 2-fold

232 increase in prescriptions for all three common PCOS symptom-management medications in PCOS and Pain cohort

compared to PCOS cohort (Figure 2).

234 Relative Risk of Future Health Outcomes for all PCOS vs. PCOS and Pain

Given that PCOS symptoms first manifest in puberty and during reproductive years, we aimed to assess the relative risk for patients with PCOS, and those with both PCOS and Pain, developing future health outcomes. We calculated the RR for matched PCOS patient cohorts with their respective controls and PCOS and Pain patient cohorts with their respective controls (see Methods). Results are visualized in **Figure 3** and cohorts counts, RRs, and p-values for differences in risk ratios are provided in **Table 5 - Figure supplement 8**.

In **Figure 3** we see the RR for both participants within the PCOS cohort (green) for 10 health outcomes and PCOS and Pain cohort (blue) for 9 health outcomes. Aside from respiratory disease, the PCOS cohort has significantly increased risk for developing the following future health outcomes compared to matched controls: mental and behavioral health, infertility, ovarian cysts, obesity, T2D, circulatory diseases, liver disease, and pain. The PCOS and Pain cohort meanwhile has significantly increased risk for developing all of the following future health outcomes compared to their matched controls: mental and behavioral health, infertility, ovarian cysts, obesity, T2D, circulatory diseases, liver disease, and kidney disease.

247 While almost all of the RR are increased for case cohorts compared to match controls, a few results stand out as 248 being particularly interesting. Infertility, for example, a common complication associated with PCOS, has a RR of 249 3.49 (95% CI 3.40-3.60) in PCOS cases overall. While still statistically significant, the RR is much lower, 1.12 (95% CI 1.08-1.17), in PCOS and Pain cases. This difference in relative risks has a p-value of 6.0x10⁻⁴⁸⁴ (Table 5 -250 251 Figure supplement 8). On the other hand, ovarian cysts have a RR of 1.52 (95% CI 1.49-1.55) in PCOS cases 252 overall but an even higher RR in PCOS and Pain cases (RR=2.31, 95% CI 2.23-2.39). This relative risk difference is 253 also significant with a p-value of 1.25×10^{-45} (Table 5 -- Figure supplement 8). In addition, mental health 254 conditions, circulatory diseases, and respiratory diseases all had higher RRs in PCOS and Pain cases vs. controls compared to PCOS cohort cases compared to controls (Figure 3, Table 5 - Figure supplement 8). We see that 255 256 mental health conditions, circulatory diseases, and respiratory diseases are 1.32 (95% CI 1.29-1.34), 1.41 (95% CI 257 1.38-1.44), and 1.35 (95% CI 1.33-1.38) in the PCOS and Pain cohort compared to 1.08 (95% CI 1.07-1.09), 1.21

258 (95% CI 1.19-1.22), and 0.87 (95% CI 0.86-0.88) in the entire PCOS cohort at statistical significance (Figure 3,

259 Table 5 - Figure supplement 8).

PCOS and PCOS and Pain cohorts were at comparable increased risk for developing future liver disease and kidney disease. For liver disease, the RR in the PCOS cohort was 2.03 (95% CI 1.98-2.08) while the RR in the PCOS and Pain cohort was 1.89 (95% CI 1.82-1.97). For kidney disease, the RR of the PCOS cohort was 1.22 (95% CI 1.16-1.28) while the RR for the PCOS and Pain cohort was 1.35 (95% CI 1.24-1.46) (**Figure 3**). The relative risk difference was statistically significant for liver disease (p-value = 3.91×10^{-06}) but not for kidney disease (p-value = 4.66×10^{-02}) (**Table 5 - Figure supplement 8**).

266 Obesity and T2D had increased risk for the PCOS cohort compared to the PCOS and Pain cohort. Obesity had a RR

267 of 1.94 (95% CI 1.92-97) in the PCOS cohort compared to 1.15 (95% CI 1.12-1.17) in the PCOS and Pain cohort.

268 Meanwhile, the RR for T2D was 2.59 (95% CI 2.53-2.66) in the PCOS cohort compared to 1.16 (95% CI 1.12-1.20)

in the PCOS and Pain cohort (Figure 3). The relative risk difference was statistically significant for both obesity (p-

value = 7.78×10^{-297}) and T2D liver disease (p-value = 6.72×10^{-307}) (**Table 5 - Figure supplement 8**).

271 Relative Risk of Future Health Outcomes Stratified by Self-Reported Race

Since we observed an increased risk for future health outcomes for both the PCOS and PCOS and Pain cohorts compared to their respective controls, we next investigated if there were any race-specific risks (self-reported from EHR) for these outcomes. We stratified the PCOS case and control cohorts by self-reported race and calculated RR for pain (dysmenorrhea or abdominal and pelvic pain). There was no significant difference in RR between selfreported race groups for PCOS cases compared to matched controls (**Figure 4A**).

When examining the PCOS and Pain cohort, we observe race-specific differences in RR for a number of future health outcomes. **Figure 4B** shows that infertility has the highest RR in the Black or African American cohort with PCOS and Pain (RR = 3.94, 95% CI 3.41-5.54) followed by Other (RR = 3.46, 95% CI 2.78-4.31), White (RR = 2.75, 95% CI 2.58-2.93), and Asian (RR = 2.22, 95% CI 1.74-2.84). The RR difference between the self-reported Asian and Black cohorts, Asian and Other cohorts, and Black or African American and White cohorts, and Other and White cohorts were all statistically significant with a p-value less than 0.05 (**Figure 4B, Table 6 - Figure supplement 9, Table 7 - Figure supplement 10**). On the other hand, liver diseases (**Figure 4I**) had the highest RR

284 in the Asian cohort (RR = 2.50, 95% CI 1.95-3.20) with PCOS and Pain followed by Black or African American 285 (RR = 2.22, 95% CI 1.94-2.55), Other (RR = 2.07, 95% CI 1.77-2.41), and White (RR = 2.01, 95% CI 1.92-2.10). 286 however, none of these RR differences were statistically significant across self-reported race groups (Table 6 -287 Figure supplement 9, Table 7 - Figure supplement 10). Ovarian cysts (Figure 4C) had the highest RR in the Black or African American cohort (RR = 2.09, 95% CI 1.91-2.30) and Other cohort (RR = 2.04, 95% CI 1.78-2.34) 288 289 compared to the Asian (RR = 1.82, 95% CI 1.48-2.46) and White (RR = 1.84, 95% CI 1.77-1.92) cohorts. 290 Meanwhile, there were similar trends for obesity (Figure 4D) and T2D (Figure 4E) where the Black or African 291 American cohort had lower RRs than the other three self-reported race cohorts (Table 6 - Figure supplement 9). There were significant RR difference between the Asian and Black or African American cohorts ($p=1.12X10^{-02}$), 292 Black or African American and Other cohorts (p=9.38X10⁻⁰³), and Black or African American and White cohorts 293 294 (p=2.17X10⁻⁰⁵) for obesity but not T2D (Figure 4D, Table 7 - Figure supplement 10). Mental health disorders 295 (Figure 4F) had an increased RR for the Asian cohort (RR=1.25, 9%% CI 1.11-1.41) while the other self-reported 296 race groups did not have significantly increased RRs. However, there was a significant difference in RR for the Asian and Other cohorts (p-value = 2.02×10^{-02}) Oppositely, kidney disease (**Figure 4D**) had a slightly increased RR 297 298 (RR=1.13, 9%% CI 1.03-1.24) in the White cohort while the other self-reported race groups did not have 299 significantly increased RRs (Table 6 - Figure supplement 9). Circulatory disease (Figure 4G) had increased RRs 300 in all four self-reported race groups, but there was no significant difference among them (Table 7 - Figure 301 supplement 10). And finally, respiratory disease (Figure 4H) had decreased RRs in Asian (RR=0.91, 9%% CI 302 0.83-0.99), Other (RR=0.90%, CI 0.85-0.96), and White (RR=0.93, 9% CI 0.92-0.95) cohorts but no increased or 303 decreased risk in the Black or African American cohort (RR=1.01, 9%% CI 0.91-1.07) (Supplemental Table 6). 304 The difference in RR between the Black or African American cohort and the three other self-reported race groups 305 were statistically significant with a p-value less than 0.05 (Figure 4H, Table 7 - Figure supplement 10).

306 Medications prescribed to patients with PCOS may modify pain prevalence

307 Since women with PCOS are often prescribed medications to help their PCOS symptoms, we aimed to investigate if 308 there were any changes in the pain diagnoses after being prescribed systemic contraceptives (COCPs), metformin, or 309 spironolactone. For patients with PCOS who were prescribed each of the three medications exclusively, we 310 calculated the percent who reported dysmenorrhea or abdominal and pelvic pain both before and after the

311 prescription (see Methods). We found that there were 88,616 women with PCOS who were prescribed systemic 312 contraceptives, 56,195 prescribed metformin, and 11,358 prescribed spironolactone. The prevalence of abdominal 313 and pelvic pain diagnosis was 6-8X greater than that of a dysmenorrhea diagnosis for PCOS participants before they 314 were prescribed PCOS-related medications (**Figure 5**).

315 As can be observed in Figure 5, participants with PCOS reported abdominal and pelvic pain at a prevalence of 316 30.1%, 25.8%, and 22.6% respectively before their first prescription of COCPs, metformin, and spironolactone. At 317 least 3-months after being prescribed a PCOS-associated medication, we observe a significant reduction in the 318 prevalence of abdominal and pelvic pain. After PCOS participants were prescribed all three medications we 319 observed a significant reduction in the prevalence of pain for all three medications. Spironolactone has the largest 320 reduction of pain prevalence with a -7.5% reduction of pain diagnosis after prescription compared to before. 321 followed by COCPs (-5%) and metformin (-2.5%). Similar results are observed with dysmenorrhea. While lower 322 overall, there was also a deceased prevalence of pain for all three medications, the prevalence for dysmenorrhea was 323 8.6%, 4.1% and 3.1% for participants with PCOS prescribed COCPs, spironolactone and metformin respectively. 324 Unlike with abdominal and pelvic pain, COCP prescriptions were associated with the largest decrease in 325 dysmenorrhea prevalence (-3.2%), followed by spironolactone (-2.5%), and (-1.4%).

326 Discussion

327 Polycystic ovary syndrome is the most prevalent endocrine disorder among women(Mousa & Tay, 2023; Walters et 328 al., 2018). Diagnosis and treatment plans are customized based on the symptoms presented by women. However, an 329 important yet often overlooked variable is pain, which may manifest as dysmenorrhea, abdominal, or pelvic pain. 330 The use of EHR data has facilitated access to patient records containing longitudinal clinical information, utilizing the readily available International Classification of Diseases (ICD) codes^{16,(Wu et al., 2016)}. Our study aimed to elucidate 331 332 the prevalence and impact of pain among individuals with PCOS, as well as to investigate the relative risk of future 333 health outcomes and the effectiveness of commonly prescribed medications on pain. Firstly, we observed a 334 significantly higher prevalence of pain among women with PCOS compared to those without the condition. 335 Specifically, 19.21% of women with PCOS reported experiencing pain, compared to 15.8% in the non-PCOS 336 cohort. This increased prevalence reveals the substantial burden of pain as a symptom of PCOS, which often goes 337 underreported and undertreated. Our demographic analysis of women with PCOS and Pain also revealed a

338 difference in diagnosis of pain across self-reported race groups and was especially high in the Black or African 339 American population (32.11%) and White population (30.75%). These findings suggest that pain is a significant, yet 340 often under-recognized, symptom of PCOS that can vary across different demographic groups. The high prevalence 341 of pain underscores the need for healthcare clinicians to routinely assess and address pain in the management of 342 PCOS, particularly in racially diverse populations. The diversity in pain perception and reporting among different 343 racial groups can be influenced by a variety of factors, including genetic differences, cultural attitude towards pain, 344 access to healthcare, and socioeconomic status. Women of different racial groups often experience different 345 severities in pain (Portenoy et al., 2004). This can lead to disparities in pain management and treatment 346 outcomes(Campbell & Edwards, 2012; Jamieson & Steege, 1996). Additionally, cultural differences may also affect 347 how individuals report pain and their willingness to seek medical help(Hadjiconstantinou et al., 2017).

348 PCOS manifests with many other concomitant conditions.(Anagnostis et al., 2018; Asuncion et al., 2000; Balen et 349 al., 2016; Escobar-Morreale et al., 2011; Hadjiconstantinou et al., 2017; Kitzinger & Willmott, 2002; Patel, 2018). 350 Our study revealed that women with PCOS and Pain have at least a 2-fold increased prevalence of other health 351 conditions at baseline compared to women with PCOS in general. The prevalence of obesity in the PCOS and Pain 352 cohort was 34.68% compared to a 16.11% prevalence in the entire PCOS cohort Excess abdominal visceral fat is 353 well-documented to increase inflammation(Després, 2012) and PCOS is considered a pro-inflammatory condition 354 linked with cardiovascular disease (CVD) and T2D. This inflammation underlies obesity, CVD, insulin resistance 355 (IR) (Abraham Gnanadass et al., 2021; Osborn & Olefsky, 2012). Our data show that 22.23% of patients with PCOS 356 and Pain also had a diagnosis for disease of the circulatory system and 9.05% of PCOS and Pain patients had a T2D 357 diagnosis. These results underscore the health challenges faced by individuals dealing with both PCOS and Pain 358 issues necessitating treatment approaches that address both the syndrome itself and its accompanying symptoms.

Women with PCOS are significantly at risk for future health outcomes such as infertility, T2D, coronary heart disease, dyslipidemia, depression, non-alcoholic fatty liver disease, and obstructive sleep(Anagnostis et al., 2018; Ávila et al., 2014; Chaudhuri, 2023; McGowan, 2011; Patel, 2018; Zore et al., 2017). Our results also highlight specific risks for different subgroups (PCOS overall and PCOS and Pain). In the overall PCOS cohort, the highest risks are for infertility (RR = 3.49) and T2D (RR = 2.59). However, in patients with PCOS and Pain, the highest risks are for ovarian cysts (RR = 2.31) and liver disease (RR = 1.89). Ovarian cysts are a hallmark feature of

365 polycystic ovarian morphology (PCOM) which is caused by immature/ arrested follicles that do not ovulate and 366 cause a "string of pearls" appearance and enlarging of the ovaries (Adashi et al., 2023; Tsilchorozidou et al., 2004). 367 Ovarian cysts have long been disputed by the PCOS research community as not being associated with PCOS and 368 therefore, not being associated with pain. However, the magnitude of this risk as shown in our results underscores 369 the importance of regular monitoring and appropriate management strategies for patients presenting with both PCOS 370 and pain symptoms. PCOS is known to be linked with non-alcoholic fatty liver disease (NAFLD)(Butt & Devi, 371 2024; Kumarendran et al., 2018; Torres & Harrison, 2016). This association between PCOS and pain and liver 372 disease may be explained by the shared metabolic disturbances common to both PCOS and NAFLD, such as insulin 373 resistance and dyslipidemia(Georgescu, 2022; Qu et al., 2013; Torres & Harrison, 2016). The presence of chronic 374 pain could potentially exacerbate these metabolic imbalances through various mechanisms, including altered stress 375 responses and lifestyle factors(Kivimäki et al., 2023). These findings suggest that patients with PCOS who also 376 experience chronic pain may represent a distinct phenotype with unique risk profiles. Additionally, the increased 377 risk for future health conditions in the PCOS and Pain cohort also suggest that pain may be an important marker for 378 identifying individuals at future health outcomes, necessitating more vigilant monitoring and proactive intervention.

379 Lastly, our analysis also delved into the impact of common PCOS medications on pain management. We found that 380 the prescribing of COCPs, metformin, and spironolactone was associated with a reduction in reported pain 381 symptoms. Specifically, individuals who received these medications showed a 3.68% average decreased prevalence 382 of pain diagnoses after treatment, suggesting that these medications may also manage pain symptoms in individuals 383 with PCOS. A recent publication looked at the association of PCOS-related medications with adverse drug reactions 384 (ADRs) for women with PCOS and found that metformin and COCPs was significantly associated with abdominal 385 pain (Sidra et al., 2019). However, this study did not measure the association with ADRs with pain before and after 386 the prescription of PCOS medication. These results offer insights for application showing that efficient 387 pharmacological management of PCOS symptoms can also help alleviate associated pain. Additionally, the efficacy 388 of these medications in reducing pain, specifically spironolactone and COCPs, which are prescribed in PCOS for 389 their antiandrogenic effects, may suggest hyperandrogenism to be a contributor to increased pain in PCOS, and a 390 potential target for addressing pain in PCOS. Furthermore, the advantages of these treatments may be beneficial, not 391 just in managing typical PCOS symptoms, but also in tackling the significant burden of pain experienced by many 392 women with PCOS highlights a valuable role in drug repurposing.

393 Our study has limitations that need to be considered when interpreting the findings. Firstly, relying on ICD codes to 394 identify pain and other health outcomes may not capture the range of experiences and clinical intricacies. While 395 these codes offer an approach to data collection, they might not fully reflect variations in pain severity or the 396 personal experiences of those, with PCOS(Kataria & Ravindran, 2020). Although extensive, the use of EHR data 397 may still contain gaps or discrepancies that could impact the accuracy of our results (Madden et al., 2016). 398 Furthermore, since this study is observational, by nature it cannot establish a causal relationship between PCOS, 399 pain and future health outcomes. Moreover, the demographic variations observed—especially the higher occurrence 400 of pain among individuals-could be influenced by socio-economic factors, access to healthcare, nutrition and other unmeasured variables. In addition, self-reported race was not captured the same globally as it is not a variable that is 401 402 coded by HCOs world-wide. Lastly, TriNetX captures only medication prescriptions, which does not allow our 403 analysis to consider adherence issues, dosage differences, or concurrent treatments that may influence the outcomes 404 observed. Future research should focus on overcoming these limitations through studies with detailed clinical 405 assessments and a broader range of demographic and socio-economic factors.

406 Conclusion

407 Various pain subtypes can profoundly affect the daily lives of PCOS patients. Due to limited research in clinical and 408 laboratory settings, the effects and underlying mechanisms of pain remain unclear. Our study highlights the 409 significant prevalence and impact of pain in women with PCOS, revealing critical differences across racial groups 410 and underscoring the heightened risk for future health complications in those experiencing pain. These findings 411 emphasize the importance of comprehensive pain assessment, management and inclusion as guidelines in the 412 standard care of PCOS, with a particular focus on addressing racial disparities. Additionally, the observed 413 effectiveness of medications such as systemic oral contraceptives, metformin, and spironolactone in reducing pain 414 symptoms provides valuable insights for clinical practice, suggesting that these treatments can offer dual benefits in 415 managing both PCOS and associated pain. Dysmenorrhea, abdominal, and pelvic pain are common experiences in 416 women with PCOS, in the absence of pelvic-related conditions that can contribute to this type of pain such as pelvic 417 inflammatory disease, endometriosis, and fibroids. It is crucial to distinguish between pain originating from PCOS 418 and Pain arising from comorbidities to ensure appropriate management and targeted treatment strategies for 419 improving the quality of life in affected individuals.

420 Funding

- 421 Tess Cherlin was supported by NIH | National Institute of General Medical Sciences (NIGMS) (grant #
- 422 K12GM081259 (HHS))

423 Conflict of Interest

424 Authors declare they have no financial interests to disclose.

425 Authors' Contributions

- 426 SSV, SO, and KS conceived and supervised the study. TC and SSV designed the methods. TC performed the
- 427 analysis, analyzed the data and designed the figures. SM and TC wrote the manuscript. All authors interpreted the
- 428 results. All authors read, edited, and approved the final manuscript.

429 Compliance with Ethical Standards

430 Not Applicable

431 Data Sharing

432 All summary-level data has all been included in this manuscript.

433 Acknowledgements

- 434 We would like to acknowledge the patients in the TriNetX Global Network without whom this work would not be
- 435 possible.

436 Disclosure

437 AI Generative (ChatGPT) was used as a language editing tool.

438

- 439
- 440
- 441
- 442
- 443

444	
445	
446	
447	
448	
449	
450	
451	References
452	Abraham Gnanadass, S., Divakar Prabhu, Y., & Valsala Gopalakrishnan, A. (2021). Association of metabolic and
453	inflammatory markers with polycystic ovarian syndrome (PCOS): an update. Archives of Gynecology and
454	Obstetrics, 303, 631-643.
455	Adashi, E. Y., Cibula, D., Peterson, M., & Azziz, R. (2023). The polycystic ovary syndrome: the first 150 years of
456	study. F&S Reports, 4(1), 2-18.
457	Altman, D. G., & Bland, J. M. (2003). Interaction revisited: the difference between two estimates. BMJ, 326(7382),
458	219.
459	Anagnostis, P., Tarlatzis, B. C., & Kauffman, R. P. (2018). Polycystic ovarian syndrome (PCOS): Long-term
460	metabolic consequences. Metabolism, 86, 33-43.
461	Asuncion, M., Calvo, R. M., San Millán, J. L., Sancho, J., Avila, S., & Escobar-Morreale, H. c. F. (2000). A
462	prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from
463	Spain. The Journal of Clinical Endocrinology & Metabolism, 85(7), 2434-2438.
464	Austin, P. C. (2011). An introduction to propensity score methods for reducing the effects of confounding in
465	observational studies. Multivariate behavioral research, 46(3), 399-424.
466	Ávila, M. A. P. d., Bruno, R. V., Barbosa, F. C., Andrade, F. C. d., & Nardi, A. E. (2014). Polycystic ovary
467	syndrome: implications of metabolic dysfunction. Revista do Colégio Brasileiro de Cirurgiões, 41, 106-
468	110.
469	Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B.,
470	Teede, H. J., & Yildiz, B. O. (2016). Polycystic ovary syndrome. Nature Reviews Disease Primers, 2(1),
471	16057. <u>https://doi.org/10.1038/nrdp.2016.57</u>

- 472 Balen, A. H., Morley, L. C., Misso, M., Franks, S., Legro, R. S., Wijeyaratne, C. N., Stener-Victorin, E., Fauser, B.
- 473 C., Norman, R. J., & Teede, H. (2016). The management of anovulatory infertility in women with
 474 polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO

475 guidance. *Human reproduction update*, 22(6), 687-708.

- 476 Butt, A. S., & Devi, J. (2024). Polycystic ovary syndrome and nonalcoholic fatty liver disease. In *Polycystic Ovary*477 *Syndrome* (pp. 92-99). Elsevier.
- 478 Campbell, C. M., & Edwards, R. R. (2012). Ethnic differences in pain and pain management. *Pain management*,
 479 2(3), 219-230.
- 480 Chaudhuri, A. (2023). Polycystic ovary syndrome: Causes, symptoms, pathophysiology, and remedies. *Obesity*481 *Medicine*, 39, 100480.
- 482 Cronin, L., Guyatt, G., Griffith, L., Wong, E., Azziz, R., Futterweit, W., Cook, D., & Dunaif, A. (1998).
 483 Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary
 484 syndrome (PCOS). *The Journal of Clinical Endocrinology & Metabolism*, 83(6), 1976-1987.
- 485 Després, J.-P. (2012). Abdominal obesity and cardiovascular disease: is inflammation the missing link? *Canadian*486 *Journal of Cardiology*, 28(6), 642-652.
- 487 Drosdzol, A., Skrzypulec, V., Mazur, B., & Pawlińska-Chmara, R. (2007). Quality of life and marital sexual
 488 satisfaction in women with polycystic ovary syndrome. *Folia histochemica et cytobiologica*, 45(I), 93-97.
- Elsenbruch, S., Hahn, S., Kowalsky, D., Öffner, A. H., Schedlowski, M., Mann, K., & Janssen, O. E. (2003).
 Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome.

491 The Journal of Clinical Endocrinology & Metabolism, 88(12), 5801-5807.

- 492 Escobar-Morreale, H. F., Luque-Ramírez, M., & González, F. (2011). Circulating inflammatory markers in
 493 polycystic ovary syndrome: a systematic review and metaanalysis. *Fertility and sterility*, 95(3), 1048-1058.
 494 e1042.
- ESHRE, T. R., & Group, A.-S. P. C. W. (2004). Revised 2003 consensus on diagnostic criteria and long-term health
 risks related to polycystic ovary syndrome. *Fertility and sterility*, *81*(1), 19-25.
- 497 Georgescu, C. E. (2022). Polycystic ovary syndrome and nonalcoholic fatty liver disease. In *Polycystic Ovary*498 *Syndrome* (pp. 187-216). Elsevier.

- Guo, S., & Fraser, M. W. (2014). *Propensity score analysis: Statistical methods and applications* (Vol. 11). SAGE
 publications.
- Hadjiconstantinou, M., Mani, H., Patel, N., Levy, M., Davies, M., Khunti, K., & Stone, M. (2017). Understanding
 and supporting women with polycystic ovary syndrome: a qualitative study in an ethnically diverse UK
 sample. *Endocrine connections*, 6(5), 323-330.
- Hahn, S., Janssen, O. E., Tan, S., Pleger, K., Mann, K., Schedlowski, M., Kimmig, R., Benson, S., Balamitsa, E., &
- 505 Elsenbruch, S. (2005). Clinical and psychological correlates of quality-of-life in polycystic ovary 506 syndrome. *European journal of endocrinology*, *153*(6), 853-860.
- 507 Haukoos, J. S., & Lewis, R. J. (2015). The propensity score. *Jama*, *314*(15), 1637-1638.
- Jamieson, D. J., & Steege, J. F. (1996). The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable
 bowel syndrome in primary care practices. *Obstetrics & Gynecology*, 87(1), 55-58.
- 510 Kataria, S., & Ravindran, V. (2020). Electronic health records: a critical appraisal of strengths and limitations.
 511 *Journal of the Royal College of Physicians of Edinburgh*, 50(3), 262-268.
- 512 Kitzinger, C., & Willmott, J. (2002). 'The thief of womanhood': women's experience of polycystic ovarian
 513 syndrome. *Social science & medicine*, 54(3), 349-361.
- 514 Kivimäki, M., Bartolomucci, A., & Kawachi, I. (2023). The multiple roles of life stress in metabolic disorders.
 515 *Nature Reviews Endocrinology*, *19*(1), 10-27.
- Kruse, C. S., Stein, A., Thomas, H., & Kaur, H. (2018). The use of electronic health records to support population
 health: a systematic review of the literature. *Journal of medical systems*, *42*(11), 214.
- 518 Kumarendran, B., O'Reilly, M. W., Manolopoulos, K. N., Toulis, K. A., Gokhale, K. M., Sitch, A. J., Wijeyaratne,
- C. N., Coomarasamy, A., Arlt, W., & Nirantharakumar, K. (2018). Polycystic ovary syndrome, androgen
 excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United
 Kingdom primary care database. *PLoS medicine*, *15*(3), e1002542.
- Lamping, D. L., Rowe, P., Clarke, A., Black, N., & Lessof, L. (1998). Development and validation of the
 menorrhagia outcomes questionnaire. *BJOG: An International Journal of Obstetrics & Gynaecology*,
 105(7), 766-779.

- 525 Li, Y., Li, Y., Ng, E. H. Y., Stener-Victorin, E., Hou, L., Wu, T., Han, F., & Wu, X. (2011). Polycystic ovary
- syndrome is associated with negatively variable impacts on domains of health-related quality of life:
 evidence from a meta-analysis. *Fertility and sterility*, *96*(2), 452-458.
- Madden, J. M., Lakoma, M. D., Rusinak, D., Lu, C. Y., & Soumerai, S. B. (2016). Missing clinical and behavioral
 health data in a large electronic health record (EHR) system. *Journal of the American Medical Informatics*
- **530** *Association*, *23*(6), 1143-1149.
- Maletzky, A., Böck, C., Tschoellitsch, T., Roland, T., Ludwig, H., Thumfart, S., Giretzlehner, M., Hochreiter, S., &
 Meier, J. (2022). Lifting hospital electronic health record data treasures: challenges and opportunities. *JMIR Medical Informatics*, 10(10), e38557.
- McGowan, M. P. (2011). Polycystic ovary syndrome: a common endocrine disorder and risk factor for vascular
 disease. *Current treatment options in cardiovascular medicine*, *13*(4), 289-301.
- McHorney, C. A., Ware Johne, J., & ANASTASIAE, R. (1993). The MOS 36-Item Short-Form Health Survey (SF36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. *Medical care*, *31*(3), 247-263.
- Mousa, A., & Tay, C. T. (2023). Technical Report for the 2023 International Evidence-based Guideline for the
 Assessment and Management of Polycystic Ovary Syndrome: 2023 Update.
- 541 Organization, W. H. (28 June 2023). *Polycystic ovary syndrome*. World Health Organization.
- 542 Osborn, O., & Olefsky, J. M. (2012). The cellular and signaling networks linking the immune system and
 543 metabolism in disease. *Nature medicine*, 18(3), 363-374.
- Patel, S. (2018). Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. *The Journal of steroid biochemistry and molecular biology*, 182, 27-36.
- Penrod, N., Okeh, C., Velez Edwards, D. R., Barnhart, K., Senapati, S., & Verma, S. S. (2023). Leveraging
 electronic health record data for endometriosis research. *Frontiers in Digital Health*, *5*, 1150687.
- Portenoy, R. K., Ugarte, C., Fuller, I., & Haas, G. (2004). Population-based survey of pain in the United States:
 differences among white, African American, and Hispanic subjects. *The journal of pain*, 5(6), 317-328.
- Qu, Z., Zhu, Y., Jiang, J., Shi, Y., & Chen, Z. (2013). The clinical characteristics and etiological study of
 nonalcoholic fatty liver disease in Chinese women with PCOS. *Iranian journal of reproductive medicine*, *11*(9), 725.

- Sidra, S., Tariq, M. H., Farrukh, M. J., & Mohsin, M. (2019). Evaluation of clinical manifestations, health risks, and
 quality of life among women with polycystic ovary syndrome. *PloS one*, *14*(10), e0223329.
- 555 Stein, I. F., & Leventhal, M. L. (1935). Amenorrhea associated with bilateral polycystic ovaries. *American journal*
- 556 of obstetrics and gynecology., 29(2), 181-191. <u>https://doi.org/10.1016/S0002-9378(15)30642-6</u>
- 557 Teede, H., Deeks, A., & Moran, L. (2010). Polycystic ovary syndrome: a complex condition with psychological,
- reproductive and metabolic manifestations that impacts on health across the lifespan. *BMC Medicine*, 8(1),
- **559** 41. <u>https://doi.org/10.1186/1741-7015-8-41</u>
- 560 Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., & Norman, R. J. (2018).
- Recommendations from the international evidence-based guideline for the assessment and management of
 polycystic ovary syndrome. *Human reproduction*, *33*(9), 1602-1618.
- Torres, D. M., & Harrison, S. A. (2016). Nonalcoholic Fatty Liver Disease: Clinical Features, Disease Modifiers,
 and Natural History. *Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside*, 183-194.
- Tsilchorozidou, T., Overton, C., & Conway, G. S. (2004). The pathophysiology of polycystic ovary syndrome.
 Clinical endocrinology, 60(1), 1-17.
- Walters, K. A., Gilchrist, R. B., Ledger, W. L., Teede, H. J., Handelsman, D. J., & Campbell, R. E. (2018). New
 perspectives on the pathogenesis of PCOS: neuroendocrine origins. *Trends in Endocrinology* & *Metabolism*, 29(12), 841-852.
- Wu, P.-Y., Cheng, C.-W., Kaddi, C. D., Venugopalan, J., Hoffman, R., & Wang, M. D. (2016). –Omic and
 electronic health record big data analytics for precision medicine. *IEEE Transactions on Biomedical Engineering*, 64(2), 263-273.
- Zawadri, J. (1992). Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. *Polycystic ovary syndrome. Current issues in endocrinology and metabolism.*
- Zhao, J., Papapetrou, P., Asker, L., & Boström, H. (2017). Learning from heterogeneous temporal data in electronic
 health records. *Journal of biomedical informatics*, 65, 105-119.
- 577 Zore, T., Joshi, N. V., Lizneva, D., & Azziz, R. (2017). Polycystic ovarian syndrome: long-term health
 578 consequences. Seminars in Reproductive Medicine,

579

Figure 1. **Analysis pipeline.** Analysis pipeline to calculate relative risk ratios (RR) for future health outcomes in PCOS (green) and PCOS and Pain (blue) cohorts for the 76859,666 women queried. STEP 1 shows the number of women in the case and controls for both the PCOS (green) and PCOS and Pain (blue) cohorts. STEP 2 shows the number of cases and controls after 1:1 propensity score matching. STEP 3 shows the different future health conditions that were considered for future health outcomes. STEP 4 shows that the final step is calculating the relative risk for the future health outcomes.




Figure 2. Prevalence of conditions and medications associated with PCOS and Pain. Barplots show the prevalence (%) (left y-axis) of different diseases associated with PCOS (green) and PCOS and Pain (blue) (x-axis). Purple line indicates the prevalence fold-change between the PCOS and PCOS and Pain cohorts (right y-axis).




Figure 3. Relative risk ratios for future health outcomes associated with PCOS and Pain. Relative

risk ratios (RR) (x-axis) for future health outcomes (y-axis) for both PCOS (green) and PCOS and Pain (blue) cohorts. Darker hued circles indicate RR, while lighter hued boxes indicate the 95% confidence intervals. The black dashed line is set 1 and is the threshold for RR, where > 1 is increased RR and < 1 is decreased RR.




Figure 4 Parts A-J. Self-reported race-stratified relative risk ratios for future health outcomes.

Relative risk ratios (RR) for future health outcomes (y-axis) stratified by self-reported race. Colors represent different self-reported race groups (x-axis): Asian (orange), Black or African American (yellow), Other (red), White (purple). **A.** Light hues indicate RR calculation for entire PCOS cohort. **B-J.** Dark hues indicate RR calculation for PCOS and Pain cohorts. Error bars represent the 95% confidence intervals. Significant differences between RR are represented by asterisks (*), where p-value $\leq 0.05 = *$, p-value $\leq 0.005 = **$, p-value $\leq 0.0005 = ***$, and p-value $\leq 0.00005 = ****$. Red dashed lines is set 1 and is the threshold for RR, where > 1 is increased RR and < 1 is decreased RR.




Figure 5. Prevalence of Pain for women with PCOS before and after medications. Prevalence (%)

changes (y-axis) of pain for women with PCOS cohort before and after prescription of COCPs (yellow), metformin (purple), and spironolactone (orange) (x-axis). Analysis was done separately for abdominal and pelvic pain (solid lines) and dysmenorrhea (dashed lines).




Figure 5